CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Efficacy and safety of vedolizumab in Crohn’s disease in patients from Asian countries in the GEMINI 2 study
Rupa Banerjee, Sai Wei Chuah, Ida Normiha Hilmi, Deng-Chyang Wu, Suk-Kyun Yang, Dirk Demuth, Dirk Lindner, Shashi Adsul
Intest Res. 2021;19(1):83-94.   Published online December 31, 2020
DOI: https://doi.org/10.5217/ir.2019.09160

Excel Download

Efficacy and safety of vedolizumab in Crohn’s disease in patients from Asian countries in the GEMINI 2 study
Intestinal Research. 2021;19(1):83-94   Crossref logo
Link1 Link2 Link3

Efficacy and safety of vedolizumab in ulcerative colitis in patients from Asian countries in the GEMINI 1 study
Intestinal Research. 2021;19(1):71-82   Crossref logo
Link1 Link2 Link3

P476 Efficacy and safety of 2 vedolizumab IV regimens in patients with perianal fistulising Crohn’s disease: results of the ENTERPRISE study
Journal of Crohn's and Colitis. 2020;14(Supplement_1):S418-S419   Crossref logo
Link1 Link2

Sa1274 Efficacy and Safety of Vedolizumab With Advancing Age in Patients With Ulcerative Colitis: Results From the GEMINI 1 Study
Gastroenterology. 2015;148(4):S-278-S-279   Crossref logo
Link1 Link2

Efficacy and Safety of 2 Vedolizumab Intravenous Regimens for Perianal Fistulizing Crohn’s Disease: ENTERPRISE Study
Clinical Gastroenterology and Hepatology. 2021;   Crossref logo
Link1 Link2

Efficacy of Vedolizumab in Fistulising Crohn’s Disease: Exploratory Analyses of Data from GEMINI 2
Journal of Crohn's and Colitis. 2018;12(5):621-626   Crossref logo
Link1

Efficacy and Safety of Vedolizumab in Ulcerative Colitis and Crohn’s Disease Patients Stratified by Age
Advances in Therapy. 2017;34(2):542-559   Crossref logo
Link1 Link2 Link3

Sa1766 - Vedolizumab Treatment Persistence Up to 3 Years: Post HOC Analysis in Vedolizumab-Naïve Patients from the Gemini Long-Term Safety Study
Gastroenterology. 2018;154(6):S-387   Crossref logo
Link1 Link2

Mo1882 The Efficacy of Vedolizumab by Disease Activity and Prior Tumor Necrosis Factor α Antagonist Failure in Patients With Ulcerative Colitis or Crohn's Disease: Post Hoc Analyses From the GEMINI 1 and GEMINI 2 Studies
Gastroenterology. 2016;150(4):S804-S805   Crossref logo
Link1 Link2

Ver(s)ifying the Efficacy of Vedolizumab Therapy on Mucosal Healing in Patients With Crohn’s Disease
Gastroenterology. 2019;157(4):925-927   Crossref logo
Link1 Link2